LAUSR

Background The aim of this study was to systematically evaluate the efficacy and prognosis of acyclovir combined with naloxone in the treatment of patients with viral encephalitis (VE). Methods PubMed, Web of Science, Embase, CNKI, and WanFang Data were searched for relevant literature published between 2000 and 2021. Meta-analysis was performed using Stata16.0 software. The treatment group was treated with acyclovir combined with naloxone, and the control group was treated with acyclovir alone. Results A total of 12 studies with 986 participants were included. Compared with the control group, the treatment group could not only significantly improve the treatment response rate (OR = 5.53, 95% CI: 3.50, 8.74; P ≤ 0.001), but also reduce the incidence of adverse reactions (OR = 0.25, 95% CI: 0.17, 0.38; P ≤ 0.001). In addition, the combined treatment significantly inhibited the levels of inflammatory factors and neuron-specific enolase (NSE) in VE patients. The time for cerebrospinal fluid to return to normal (SMD = −2.73, 95% CI: −2.96, −2.51; P ≤ 0.001), as well as the disappearance time of meningeal irritation (SMD = −3.58, 95% CI: −4.96, −2.20; P ≤ 0.001), headache (SMD = −3.87, 95% CI: −5.84, −1.91; P ≤ 0.001), convulsion (SMD = −3.65, 95% CI: −4.56, −2.75; P < 0.001), tic (SMD = −4.083, 95% CI: −5.18, −2.98; P ≤ 0.001) and disturbance of consciousness (SMD = −4.96, 95% CI: −6.28, −3.63; P ≤ 0.001) in the treatment group were significantly shorter than those in the control group. Conclusion A combination of acyclovir and naloxone can reduce the inflammatory response and shorter the time to symptom relief and disappearance, which is worthy of clinical promotion.